Abstract CT228: Talazoparib (Tala) in patients (pts) with solid tumors with ATM alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Publication
, Conference
Dib, EG; Rothe, M; Mangat, PK; Garrett-Mayer, E; Bivins, D; Gitau, M; Ganti, AK; Winer, A; Suhag, V; Outlaw, D; Hall, MJ; Alese, OB; Yan, F ...
Published in: Cancer Research
April 25, 2025
Duke Scholars
Published In
Cancer Research
DOI
EISSN
1538-7445
ISSN
0008-5472
Publication Date
April 25, 2025
Volume
85
Issue
8_Supplement_2
Start / End Page
CT228 / CT228
Publisher
American Association for Cancer Research (AACR)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3101 Biochemistry and cell biology
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Dib, E. G., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Bivins, D., Gitau, M., … Schilsky, R. L. (2025). Abstract CT228: Talazoparib (Tala) in patients (pts) with solid tumors with ATM alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. In Cancer Research (Vol. 85, pp. CT228–CT228). American Association for Cancer Research (AACR). https://doi.org/10.1158/1538-7445.am2025-ct228
Dib, Elie G., Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Dustin Bivins, Mark Gitau, Apar K. Ganti, et al. “Abstract CT228: Talazoparib (Tala) in patients (pts) with solid tumors with ATM alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” In Cancer Research, 85:CT228–CT228. American Association for Cancer Research (AACR), 2025. https://doi.org/10.1158/1538-7445.am2025-ct228.
Dib EG, Rothe M, Mangat PK, Garrett-Mayer E, Bivins D, Gitau M, et al. Abstract CT228: Talazoparib (Tala) in patients (pts) with solid tumors with ATM alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. In: Cancer Research. American Association for Cancer Research (AACR); 2025. p. CT228–CT228.
Dib, Elie G., et al. “Abstract CT228: Talazoparib (Tala) in patients (pts) with solid tumors with ATM alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” Cancer Research, vol. 85, no. 8_Supplement_2, American Association for Cancer Research (AACR), 2025, pp. CT228–CT228. Crossref, doi:10.1158/1538-7445.am2025-ct228.
Dib EG, Rothe M, Mangat PK, Garrett-Mayer E, Bivins D, Gitau M, Ganti AK, Winer A, Suhag V, Outlaw D, Hall MJ, Alese OB, Nazemzadeh R, Pisick E, Yan F, Hafez N, Calfa CJ, Leonhardt L, DeRemer D, Gregory A, Hinshaw DC, Grantham GN, Halabi S, Schilsky RL. Abstract CT228: Talazoparib (Tala) in patients (pts) with solid tumors with ATM alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Cancer Research. American Association for Cancer Research (AACR); 2025. p. CT228–CT228.
Published In
Cancer Research
DOI
EISSN
1538-7445
ISSN
0008-5472
Publication Date
April 25, 2025
Volume
85
Issue
8_Supplement_2
Start / End Page
CT228 / CT228
Publisher
American Association for Cancer Research (AACR)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3101 Biochemistry and cell biology
- 1112 Oncology and Carcinogenesis